Segment Information

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Segment Information

Segment Information

Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Company reports segment information on the basis of markets and geography, which reflects its focus on bringing its broad and diversified portfolio of branded, complex generics and generic products to people in markets everywhere. Our Developed Markets segment comprises our operations primarily in North America and Europe. Our Greater China segment includes our operations in China, Taiwan and Hong Kong. Our JANZ segment reflects our operations in Japan, Australia and New Zealand. Our Emerging Markets segment encompasses our presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company’s ARV franchise.

The Company’s chief operating decision maker is the Chief Executive Officer, who evaluates the performance of its segments based on total revenues and segment profitability.

Certain costs are not included in the measurement of segment profitability, such as costs, if any, associated with the following:

◦Intangible asset amortization expense and impairments of goodwill and long-lived assets;

◦R&D and acquired IPR&D expense;

◦Net charges or net gains for litigation settlements and other contingencies;

◦Certain costs related to transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory and property, plant and equipment; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) other significant items, which are substantive and/or unusual, and in some cases recurring, items (such as restructuring) that are evaluated on an individual basis by management and that either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such special items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for asset impairments and disposals of assets or businesses, including costs related to our planned divestitures and the Biocon Biologics Transaction, and, as applicable, any associated transition activities.

◦Corporate and other unallocated costs associated with platform functions (such as digital, facilities, legal, finance, human resources, insurance, public affairs and procurement), patient advocacy activities and certain compensation and other corporate costs (such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing, which include manufacturing variances associated with production) and operations that are not directly assessed to an operating segment as business unit (segment) management does not manage these costs.

The Company does not report depreciation expense, total assets and capital expenditures by segment, as such information is not used by the chief operating decision maker.

The accounting policies of the segments are the same as those described in Note 2 Summary of Significant Accounting Policies included in the 2022 Form 10-K.

Presented in the table below is segment information for the periods identified and a reconciliation of segment information to total consolidated information.

	Net Sales				Segment Profitability
	Three Months Ended September 30,				Three Months Ended September 30,
(In millions)	2023		2022		2023		2022
Reportable Segments:
Developed Markets	$	2,408.5	$	2,431.5	$	1,087.0	$	1,236.3
Greater China	548.4		574.0		354.6		403.5
JANZ	334.5		383.0		125.4		163.6
Emerging Markets	642.5		678.9		273.6		330.5
Total reportable segments	$	3,933.9	$	4,067.4	$	1,840.6	$	2,133.9
Reconciling items:
Intangible asset amortization expense					(584.0)		(615.9)
Globally managed research and development costs					(211.2)		(174.9)
Acquired IPR&D					(1.0)		—
Litigation settlements & other contingencies					26.1		3.9
Transaction related and other special items					(207.3)		(239.1)
Corporate and other unallocated					(411.5)		(547.8)
Earnings from operations					$	451.7	$	560.1

	Net Sales				Segment Profitability
	Nine months ended September 30,				Nine months ended September 30,
(In millions)	2023		2022		2023		2022
Reportable Segments:
Developed Markets	$	6,932.7	$	7,386.7	$	3,085.4	$	3,703.1
Greater China	1,645.1		1,695.4		1,098.6		1,214.0
JANZ	1,052.2		1,233.9		387.5		496.0
Emerging Markets	1,932.5		2,035.0		863.5		976.8
Total reportable segments	$	11,562.5	$	12,351.0	$	5,435.0	$	6,389.9
Reconciling items:
Intangible asset amortization expense					(1,778.5)		(1,898.1)
Intangible asset disposal & impairment charges					(32.0)		—
Globally managed research and development costs					(602.4)		(479.8)
Acquired IPR&D					(11.2)		—
Litigation settlements & other contingencies					36.5		(13.2)
Transaction related and other special items					(620.4)		(651.8)
Corporate and other unallocated					(1,206.4)		(1,530.8)
Earnings from operations					$	1,220.7	$	1,816.2